Eptinezumab
Vyepti (eptinezumab) is an antibody pharmaceutical. Eptinezumab was first approved as Vyepti on 2020-02-21. The pharmaceutical is active against calcitonin; calcitonin gene-related peptide 1 and calcitonin gene-related peptide 2.
| Trade Name | Vyepti |
|---|---|
| Common Name | Eptinezumab |
| Indication | |
| Drug Class | Monoclonal antibodies: humanized, neural indications |
